KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) Equity Income (2021 - 2025)

Thermo Fisher Scientific (TMO) has disclosed Equity Income for 4 consecutive years, with $33.0 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Equity Income rose 3400.0% year-over-year to $33.0 million, compared with a TTM value of -$42.0 million through Dec 2024, up 28.81%, and an annual FY2025 reading of -$41.0 million, up 2.38% over the prior year.
  • Equity Income was $33.0 million for Q4 2024 at Thermo Fisher Scientific, up from -$14.0 million in the prior quarter.
  • Across five years, Equity Income topped out at $33.0 million in Q4 2024 and bottomed at -$84.0 million in Q2 2024.
  • Average Equity Income over 4 years is -$19.8 million, with a median of -$16.5 million recorded in 2023.
  • The sharpest move saw Equity Income plummeted 5000.0% in 2022, then skyrocketed 3400.0% in 2024.
  • Year by year, Equity Income stood at -$3.0 million in 2021, then tumbled by 900.0% to -$30.0 million in 2022, then surged by 96.67% to -$1.0 million in 2023, then surged by 3400.0% to $33.0 million in 2024.
  • Business Quant data shows Equity Income for TMO at $33.0 million in Q4 2024, -$14.0 million in Q3 2024, and -$84.0 million in Q2 2024.